Toripalimab is a PD-1 blocking monoclonal antibody used for the treatment of metastatic and recurrent nasopharyngeal carcinomas. The proliferation of some cancers can be attributed, at least in part, to the suppression of host tumor surveillance.
- Mechanism
- Curator reviewed · 5 references
The binding of programmed death ligands 1 and 2 (PD-L1 and PD-L2) to the PD-1 receptor on T-cells results in the inhibition of T-cell proliferation and cytokine production - this pathway therefore plays a vital role in immune inhibition and self-tolerance. In some cancers, PD-1 ligands may be overexpressed and result in the inhibition of tumor surveillance.
Toripalimab is a monoclonal antibody directed against the PD-1 receptor. It blocks the PD-L1/PD-1 pathway, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response.
- Primary indication
- Toripalimab is indicated in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC).Curator reviewed · 4 structured indications
- Formula / weight
- 150000.0 Da
- First approval
- Canada, 2025 · United States, 2023 · European Union, 2025
- Also known as
- Toripalimab-tpzi
- Code names
- JS-001 · TAB-001
- Brand names
Resolves to
What you can answer from here — as of November 18, 2025
Which drugs share a target with Toripalimab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account